U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886113) titled 'CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial' on March 04.
Brief Summary: Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%. An alternative to current management is restoration of the volume of blood pumped by the heart (cardiac output) using a ventricular assist device. In the acute setting this is difficult but can be done using the CorVad device which is a catheter-based, axial flow pump that pumps blood directly from the left ventricle ...